Novel Peptain for Neuroprotection in Glaucoma
dc.contributor.author | Stankowska, Dorota | |
dc.contributor.author | Krishnamoorthy, Vignesh | |
dc.contributor.author | Krishnamoorthy, Raghu | |
dc.contributor.author | Chaphalkar, Renuka | |
dc.contributor.author | Nagaraj, Ram | |
dc.contributor.author | Nahomi, Rooban | |
dc.contributor.author | Nam, Mi-hyun | |
dc.contributor.author | Beall, Kallen | |
dc.contributor.author | Brodrick, Ashley | |
dc.creator | Kodati, Bindu | |
dc.date.accessioned | 2020-12-11T14:34:07Z | |
dc.date.available | 2020-12-11T14:34:07Z | |
dc.date.issued | 2020 | |
dc.description.abstract | Purpose: To determine if intravitreal administration of the core peptide of [alpha]-B crystallin, peptain-1 (P1) conjugated to a cell permeable peptide (CPP) (named P1-CPP) could inhibit retinal ganglion cell (RGC) death and functional decline in a rodent model of glaucoma. Methods: Primary RGCs were treated with endothelin-3 (ET-3) in the presence of either P1-CPP (12.5 µg/ml) or vehicle, following which RGC survival was assessed. In a different set of experiments, intraocular pressure (IOP) was elevated in one eye of Brown Norway (BN) rats and intravitreally injected with 2 µl of either P1-CPP or vehicle, once in a week for 6 weeks. RGC function was assessed by the pattern electroretinogram (PERG) amplitude. Retinal flat mounts were imaged and surviving RGCs were counted. Results: ET-3 treatment lead to 24% of RGCs loss compared to vehicle treated cells (p< 0.0001). P1-CPP treatment significantly lowered the ET-3-mediated cell loss (7% cell death, p< 0.001). IOP elevation in vehicle injected animals produced 11% and 27% loss of RGCs, in central and peripheral retina respectively, which was significantly lower in P1-CPP treated rats (7% loss in both eccentricities, **p< 0.01). P1-CPP treatment also promoted axonal protection during IOP elevation. IOP elevation caused 63% decline in the PERG amplitude (*p< 0.03) in comparison with naïve rats, which was sustained by P1-CPP treatment. Conclusion:The intravitreally injected P1-CPP provides cellular as well as functional protection of RGCs, which could facilitate neuroprotection against glaucomatous insults. | |
dc.identifier.uri | https://hdl.handle.net/20.500.12503/30140 | |
dc.language.iso | en | |
dc.title | Novel Peptain for Neuroprotection in Glaucoma | |
dc.type | poster | |
dc.type.material | text |